Table 2.

Cohort 2 (idebenone 900 mg daily): Patient characteristics and course of visual acuity

No.	Age	Sex	Mutation	Homo-/heteroplasmy	Initial visual acuity		Deterioration (time since onset)	Final visual acuity		Observation period (m)	Idebenone recovery (m)
					OD	OS		OD	OS
6	18	M	11778	Homoplasmy	0.03	0.63	0.05 (OS, 2 m)	0.05	0.80	25	13.00
7	33	M	11778	Homoplasmy	0.03	*		1.00	*	32	25.00
8	28	M	11778	Homoplasmy	0.16	0.10		0.80	0.80	20	15.00
9	14	M	MT-ND1-3733	Homoplasmy	0.03	0.01		0.0052	0.02	12
10	15	M	11778	Homoplasmy	0.02	0.03		0.0052	0.05	23
11	34	F	MT-ND1-3635	Heteroplasmy	0.10	0.50		0.01	0.50	35
12	48	M	3460	Heteroplasmy	0.63	0.00	0.04 (OD, 1 m)	0.01	0.00	20

Eyes that have improved are highlighted in italics

m months

*Patient 7: pre-existing blindness after retinal detachment of left eye